Parexel Intl Cp (PRXL) 67.41 $PRXL PAREXEL Appoints Four

Parexel Intl Cp (PRXL) 67.41 $PRXL

PAREXEL Appoints Four Executives to Senior Leadership Team
BusinessWire - Mon Aug 01, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of four company executives to its senior-most leadership team, the Business Review Committee:
PRXL: 67.41 (+0.56)

SmarTrend Watching for Potential Rebound in Shares of Parexel International After 2.64% Loss
Comtex SmarTrend(R) - Mon Jul 18, 3:22PM CDT
Parexel International (NASDAQRXL) traded in a range yesterday that spanned from a low of $63.69 to a high of $65.33. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $65.56 on volume of 355,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PRXL: 67.41 (+0.56)

PAREXEL International Announces Date of Fourth Quarter and Fiscal Year 2016 Earnings Release and Conference Call
BusinessWire - Mon Jul 11, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for Fourth Quarter and Fiscal Year 2016 on Wednesday, August 3, 2016 after the close of the stock market.
PRXL: 67.41 (+0.56)

PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2016
BusinessWire - Mon Jun 20, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that several of its experts will discuss key issues facing the industry at the 52nd Annual Drug Information Association (DIA) meeting, held from June 26-30, 2016 in Philadelphia.
PRXL: 67.41 (+0.56)

PAREXEL Invites Public to Listen to Live Webcast of Investor Day Presentations on June 30
BusinessWire - Wed Jun 15, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day presentations on Thursday, June 30, 2016, from 9:00 a.m. to 12:00 p.m. EDT.
PRXL: 67.41 (+0.56)

PAREXEL Announces Master Services Agreement with Pfizer
BusinessWire - Fri Jun 10, 1:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has signed a services agreement with Pfizer Inc. Under the terms of this agreement, PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.
PRXL: 67.41 (+0.56)

PAREXEL Named Company of the Year for the Pharmaceuticals Industry with a Gold Stevie from the American Business Awards
BusinessWire - Thu Jun 02, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, has been named Company of the Year - Pharmaceuticals in the 14th Annual American Business Awards(SM). The judges awarded PAREXEL a Gold Stevie(R) Award and recognized the Company's investments in innovation and expanded capabilities across the drug development continuum in 2015 as specifics for the accolade.
PRXL: 67.41 (+0.56)

PAREXEL International to Present at Goldman Sachs Global Healthcare Conference and Jefferies Healthcare Conference
BusinessWire - Tue May 24, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL) announced today that executives will be making a presentation on PAREXEL and discussing business developments and financial outlook at two investor conferences in June.
PRXL: 67.41 (+0.56)

PAREXEL International to Present at UBS Healthcare Conference
BusinessWire - Mon May 09, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the UBS Healthcare Conference on Tuesday, May 24, 2016, in New York City. Ingo Bank, Senior Vice President and Chief Financial Officer will be making a presentation on PAREXEL and discussing business developments at 8:30 a.m. ET.
PRXL: 67.41 (+0.56)

The Zacks Analyst Blog Highlights: Newell Brands, Hormel Foods, Shire and PAREXEL International
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Newell Brands, Hormel Foods, Shire and PAREXEL International
PRXL: 67.41 (+0.56), NWL: 53.97 (+1.51), SHPG: 194.00 (-0.12), HRL: 37.55 (+0.20)

Parexel meets 3Q profit forecasts
Automated Insights - Wed Apr 27, 3:47PM CDT
WALTHAM, Mass. (AP) _ Parexel International Corp. (PRXL) on Wednesday reported fiscal third-quarter profit of $47.9 million.
PRXL: 67.41 (+0.56)

PAREXEL International Reports Third Quarter Fiscal Year 2016 Results
BusinessWire - Wed Apr 27, 3:01PM CDT
--Adjusted operating margin of 13.3%; GAAP operating margin of 13.2%
PRXL: 67.41 (+0.56)

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:30AM CDT
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
AIRM: 32.70 (-0.59), PRXL: 67.41 (+0.56), EBS: 30.97 (-2.42), CRL: 88.44 (+0.51), MOH: 56.16 (-0.65)

4 Stocks to Avoid Sell-in-May Syndrome
Swarup Gupta - Zacks Investment Research - Wed Apr 27, 8:25AM CDT
Picking stocks from defensive sectors like consumer staples and healthcare may be a smarter option.
PRXL: 67.41 (+0.56), NWL: 53.97 (+1.51), SHPG: 194.00 (-0.12), HRL: 37.55 (+0.20)

What's in Store for TrovaGene (TROV) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:16AM CDT
TrovaGene Inc. (TROV) is expected to release first-quarter 2016 results on May 3.
BDX: 176.78 (+0.78), PRXL: 67.41 (+0.56), ALGN: 89.69 (+0.54), TROV: 5.58 (-0.05)

Will Ecolab's (ECL) Earnings Surprise Investors in Q1?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:51AM CDT
Ecolab Inc. (ECL) is slated to announce first-quarter 2016 earnings results on May 3.
BDX: 176.78 (+0.78), PRXL: 67.41 (+0.56), ALGN: 89.69 (+0.54), ECL: 118.67 (+0.29)

Nutrisystem (NTRI) Q1 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:47AM CDT
Nutrisystem Inc. (NTRI) is scheduled to release first-quarter 2016 results on May 3.
BDX: 176.78 (+0.78), PRXL: 67.41 (+0.56), ALGN: 89.69 (+0.54), NTRI: 29.54 (-0.04)

Myriad Genetics (MYGN) Q3 Earnings: A Beat in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 2:27PM CDT
Last quarter, Myriad (MYGN) posted a positive earnings surprise of 9.76%.
ZBH: 131.06 (-0.08), MYGN: 31.48 (+0.50), PRXL: 67.41 (+0.56), GILD: 80.46 (+0.99)

5 Stocks to Invest on Healthcare Rebound
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:42AM CDT
Healthcare stocks bounced back this month after being mostly out of favor during the first quarter.
AIRM: 32.70 (-0.59), PRXL: 67.41 (+0.56), EBS: 30.97 (-2.42), CRL: 88.44 (+0.51), MOH: 56.16 (-0.65)

Henry Schein (HSIC) Q1 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 8:07AM CDT
Last quarter, Henry Schein (HSIC) posted a positive earnings surprise of 1.21%
ZBH: 131.06 (-0.08), PRXL: 67.41 (+0.56), GILD: 80.46 (+0.99), HSIC: 180.14 (-0.84)